Literature DB >> 27064537

Analysis of toll-like receptor rs4986790 polymorphism in Saudi patients with primary open angle glaucoma.

Khaled K Abu-Amero1,2,3, Altaf A Kondkar1,2, Ahmed Mousa1,2, Taif A Azad1,2, Tahira Sultan1,2, Essam A Osman1, Saleh A Al-Obeidan1.   

Abstract

BACKGROUND: To investigate whether SNP rs4986790 in toll-like receptors (TLRs) is a risk factor for primary open angle glaucoma (POAG) in a Saudi population.
MATERIALS AND METHODS: A cohort of 85 unrelated POAG patients and 95 unrelated control subjects from Saudi Arabia were genotyped utilizing Taq-Man® assay. The association between mutant genotypes and various clinical indices important for POAG was investigated.
RESULTS: Among cases, the normal pattern (A/A) was detected in 70 (82.4%) of the subjects, A/G in 14 (16.5%) and G/G in one subject only (1.2%). Among controls, prevalence of the genotype (A/A) was detected in 86 (90.5%), the (A/G) genotype in 8 (8.4%) and homozygous mutated genotype (G/G) in 1 (1.1%) subjects. Comparing cases to controls, the odds ratio of having heterozygous mutation (A/G) was 2.15 [95% CI: 0.853-5.417], which was not significant (p = 0.114). The odds ratio of having homozygous mutation (G/G) was 1.22 [95% CI: 0.075-19.99], which was statistically non-significant (p = 0.568). Likewise, the presence of the mutated allele (G) was non-significantly different between cases and controls (p = 0.154). Comparing cases to controls as regards co-morbidity with other systemic diseases, there were no statistically significant differences between groups in all assessed diseases except for a family history of glaucoma (p = 0.014) Conclusions: In conclusion, we could not detect any direct link between genotypes or allele frequencies of SNP rs4986790 in the TLR4 gene and POAG. In contrast, genotype (A/A) may be protective against POAG especially among individuals with no family history of glaucoma.

Entities:  

Keywords:  Primary open angle glaucoma; Saudi Arabia; rs4986790; toll-like receptors

Mesh:

Substances:

Year:  2016        PMID: 27064537     DOI: 10.3109/13816810.2016.1151900

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  6 in total

1.  Association of Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile with the risk of primary open angle glaucoma.

Authors:  Jose Navarro-Partida; Abril Bernardette Martinez-Rizo; Pedro Ramirez-Barrera; Jesus Bernardino Velazquez-Fernandez; Veronica A Mondragon-Jaimes; Arturo Santos-Garcia; Veronica Benites-Godinez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-18       Impact factor: 3.117

2.  Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study.

Authors:  Todd E Scheetz; Ben Faga; Lizette Ortega; Ben R Roos; Mae O Gordon; Michael A Kass; Kai Wang; John H Fingert
Journal:  Ophthalmology       Date:  2016-10-01       Impact factor: 12.079

3.  The association of toll-like receptor 4 gene polymorphisms with primary open angle glaucoma susceptibility: a meta-analysis.

Authors:  Narttaya Chaiwiang; Teera Poyomtip
Journal:  Biosci Rep       Date:  2019-04-02       Impact factor: 3.840

4.  Associations between TLR4 Polymorphisms and Open Angle Glaucoma: A Meta-Analysis.

Authors:  Zhongjing Lin; Shouyue Huang; Jun Sun; Bing Xie; Yisheng Zhong
Journal:  Biomed Res Int       Date:  2019-07-24       Impact factor: 3.411

5.  Fibronectin extra domain A (FN-EDA) elevates intraocular pressure through Toll-like receptor 4 signaling.

Authors:  Amanda L Roberts; Timur A Mavlyutov; Tanisha E Perlmutter; Stacy M Curry; Sherri L Harris; Anil K Chauhan; Colleen M McDowell
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

6.  Polymorphism rs3742330 in microRNA Biogenesis Gene DICER1 Is Associated with Pseudoexfoliation Glaucoma in Saudi Cohort.

Authors:  Altaf A Kondkar; Taif A Azad; Tahira Sultan; Rakesh Radhakrishnan; Essam A Osman; Faisal A Almobarak; Glenn P Lobo; Saleh A Al-Obeidan
Journal:  Genes (Basel)       Date:  2022-03-10       Impact factor: 4.141

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.